Article Results:
[Dec 01, 2005] Questions & Comments, by Mark Robertson
We wish a joyous, safe and prosperous holiday season for all of you.
[Jan 01, 2006] Questions & Comments, by Mark Robertson
Yields, EAGLEs and LLTC.
[Jan 01, 2016] Dogs of the Dow: Howling Again?, by Mark Robertson
What happens if we utilize total return forecasts (instead of current yield) to go shopping among the Dow stocks? What can we learn about 1-year time horizons?
[Feb 01, 2007] Tin Cup Model Portfolio, by Mark Robertson
Sell Pfizer, Buy NAVTEQ.
[Jun 01, 2010] Pharmaceutical HOLDRs, by Cy Lynch
Patient investors should be especially rewarded if analysts' current expectations are overly negative.
[Dec 01, 2005] Tin Cup Model Portfolio, by Mark Robertson
Partial sale of UNH, accumulate Pfizer.
[May 01, 2009] Vanguard Healthcare, by Mark Robertson
VHT is a passively managed ETF focusing on a sub-set of companies in the healthcare sector.
[Sep 01, 2005] Sweet 16, by Mark Robertson
New this month: Fred's, Bank of New York, Meredith and Pacific Sunwear.
[Jun 01, 2005] Tin Cup Model Portfolio, by Mark Robertson
The model portfolio has performed at an exceptional level during the trailing ten year period.
[Jul 01, 2005] Tin Cup Model Portfolio, by Mark Robertson
$1,000,000 Rendezvous: 1/11/2009 (+62 days).
[Aug 01, 2005] Thompson Plumb Growth, by Mark Robertson
Thompson Plumb Growth is among a group of long-term performance leaders featured this month.
[May 01, 2005] Fidelity Blue Chip Growth, by Mark Robertson
This fund is probably a poster child for truth-in-advertising.
[Jun 01, 2005] Fidelity Dividend Growth, by Mark Robertson
For the second consecutive month, we feature a Fidelity fund as the mutual selection for study.
[Sep 01, 2005] Federated Capital Appreciation, by Mark Robertson
FEDEX appears to have the potential to return to its favorable historical performance when it ranked in the top decile of all large-cap growth funds.
[Jan 01, 2007] Summing Our Financial Strength, by Mark Robertson
A company can't be best-of-breed without a high relative financial strength.
[Apr 01, 2005] White Oak Select Growth, by Mark Robertson
The list was culled for mutual funds with the following characteristics: Projected Annual Return greater than the total stock market and a quality rating greater than 65. The result is White Oak Growth (WOGSX).
[Aug 01, 2005] Tin Cup Model Portfolio, by Mark Robertson
The model portfolio gained 5.5% during July 2005 and is up 25.7% over the trailing 52 weeks vs. 17.1% for the Wilshire 5000.
[Jun 03, 2005] Eating Crow, by Mark Robertson
Dan's back with some questions and a rather generous helping of "crow" .
[Mar 01, 2006] Tin Cup Model Portfolio, by Mark Robertson
Sell Worthington Industries, Accumulate HD & LLTC.
[Oct 01, 2005] Peak Interest In Quality Leaders, by Mark Robertson
In this issue, we introduce the MANIFEST 40, consisting of the stocks which appear most frequently on your collective dashboards.
[Mar 29, 2007] Manifest Top 40, by Mark Robertson
Our quarterly "consensus" returns with our seventh edition of the Manifest Top 40, a list of the most widely-followed stocks by subscribers.
[Oct 01, 2009] Manifest Top 40, by Mark Robertson
The three top performers in the MANIFEST TOP 40 with the largest annualized relative returns since inception are Quality Systems, Infosys Tech and FactSet Research.
[Dec 17, 2007] Christmas Countdown: StockWatch Reports, by Mark Robertson
With the release of the latest MANIFEST 40, we've decided to perform a bunch of StockWatch reports on the most widely-held residents in subscriber dashboards.
[Jul 01, 2009] Manifest Top 40, by Mark Robertson
The MANIFEST TOP 40 is now 3.75 years old. The list represents the most widely-followed companies from subscriber dashboards. The annualized rate of return for the stocks on your collective dashboards is (-3.0%) versus (-8.0%) for the Wilshire 5000.
[Apr 07, 2006] Manifest Top 40, by Mark Robertson
Manifest consensus-by-dashboard continues to perform fairly well, delivering a 13.9% rate of return but now trails the Wilshire 5000.
[Jul 01, 2006] Manifest Top 40, by Mark Robertson
In the realm of long-term investing, patience is a virtue.
[Dec 30, 2005] Manifest Top 40, by Mark Robertson
A list of the most widely-followed companies from subscriber dashboards.
[Sep 21, 2006] Manifest Top 40, by Mark Robertson
Stability within the Top 40 seems to be increasing as Home Depot continues to hold down the top position, despite some angst and shareholder discomfort.
[Dec 30, 2006] Manifest Top 40, by Mark Robertson
Our quarterly "consensus" returns with our sixth edition of the Manifest Top 40, a list of the most widely-followed stocks by subscribers.
[Dec 15, 2009] Manifest Top 40, by Mark Robertson
The three top performers in the MANIFEST TOP 40 are Cognizant Technology, Quality Systems and Infosys Tech.
[Mar 27, 2008] Manifest Top 40, by Mark Robertson
This is our 11th edition of the MANIFEST 40, covering the last 33 months. It's a list of the most widely-followed stocks by subscribers.
[Jul 01, 2007] Manifest Top 40, by Mark Robertson
Our quarterly "consensus" returns with our eighth edition of the Manifest Top 40, a list of the most widely-followed stocks by subscribers.
[Dec 17, 2008] Manifest Top 40, by Mark Robertson
The outlook continues to be favorable for the MANIFEST 40. It's the relative return that matters with a long-term perspective. We'll take +6% and wish everybody the best of the holiday season.
[May 08, 2009] Manifest Top 40, by Mark Robertson
Walgreen (WAG) continues in the lead as the company found on the highest number of subscriber dashboards. The top ten was unchanged since the December edition of the MANIFEST 40.
[Jul 01, 2008] Manifest Top 40, by Mark Robertson
This is our 12th edition of the MANIFEST 40, covering the last 3 years. It's a list of the most widely-followed stocks by subscribers.
[Sep 30, 2008] Manifest Top 40, by Mark Robertson
Our MANIFEST 40 is a list of the most widely-followed stocks by subscribers. The annualized rate of return for the stocks on our collective dashboards is 4.1% versus (0.4%) for the Wilshire 5000 since inception.
[Oct 01, 2013] Is Buy-and-Hold Dead?, by Mark Robertson
You don’t have to google very long to come up with a long list of articles and commentaries about the death of “buy and hold” as a strategy.
[Apr 01, 2016] Allergan, by Mark Robertson
AGN is a well-positioned industry leader as a stand-alone company.
[Jul 01, 2006] Tin Cup Model Portfolio, by Mark Robertson
April and May were very unkind to the likes of portfolio holdings Home Depot, Bed Bath & Beyond, Wrigley, Microsoft and UnitedHealth.
[Sep 01, 2006] A Grab for Growth Guidelines, by Mark Robertson
Should the minimum sales growth target for our model portfolio be increased.
[Aug 01, 2006] Tin Cup Model Portfolio, by Mark Robertson
The monthly contribution was used to accumulate more shares of Microsoft.
[May 01, 2009] Terminal Remodeling, by Mark Robertson
When the long-term trend is impacted, we do well to consider how our forecasts might change to reflect reasonable expectations.
[Nov 01, 2005] Tin Cup Model Portfolio, by Mark Robertson
The model portfolio has performed at an exceptional level during the trailing ten year period.
[Jun 01, 2006] American Century Ultra, by Cy Lynch
This month's fund, American Century Ultra (TWCUX), is the first previously featured fund to make a return visit.
[Oct 01, 2005] Vanguard Growth Equity, by Mark Robertson
You'll need a few ounces of courage and risk tolerance to own VGEQX but we've been impressed by the strong migration to quality.
[Jul 01, 2006] Those "Hills" and Mattress Stuffing, by Mark Robertson
It's a challenge to ignore the noise and avoid the panic while the herd of average investors heads for the hills.
[Oct 01, 2005] Tin Cup Model Portfolio, by Mark Robertson
This month's $1200 contribution (and quarterly dividends) will be invested in Masco Corp with a PAR of 20.9% and quality rating of 74.7.
[Dec 21, 2005] Dashing Thru the Dashboards, by Mark Robertson
Some Perspective and Results Update.
[Sep 01, 2021] Tin Cup Demonstration Portfolio (September 2021), by Mark Robertson
Trimming and Nudging Quality and Return Forecast ...
[Feb 01, 2010] Band of Groundhogs, by Mark Robertson
Whether you're an individual or group combatant, we can't think of a Community of long-term investors that we'd rather band together with.
Forum Post Results:
Pfizer (PFE)
· by
Mark Robertson
·
04/03/2013 10:05 AM
·
Stocks
Here’s a long-term RSI chart for Pfizer (PFE):
Pfizer (PFE)
· by
Mark Robertson
·
04/23/2006 06:40 AM
·
Stocks
The vigil awaiting an increase in the projected sales growth rate for Pfizer (PFE) will continue for a while longer. This weekend’s update dropped...
Pfizer (PFE)
· by
Mark Robertson
·
04/25/2006 01:28 PM
·
Stocks
Oh… and Pfizer dropped from the A++/100 Club (Financial Strength/EPS Pred) when PFE’s EPS Pred was reduced to 95.
Pfizer (PFE)
· by
Danny Matthews
·
04/26/2006 10:33 PM
·
Stocks
Has this drop ever been reflected in their history and how has PFE responded? (Businesswise) dannymatthews
Pfizer (PFE)
· by
Mark Robertson
·
04/27/2006 09:06 AM
·
Stocks
That’s an interesting question, Danny. It’d be interesting to see if there’s ever been a “disruption” this large in Pfizer’s history — and to see...
Pfizer (PFE)
· by
Etana Finkler
·
08/22/2006 10:02 AM
·
Stocks
At my investment club meeting last night, it was brought to my attention that Pfizer’s CEO left (fired? quit?) within the past month or so. I had...
Pfizer (PFE)
· by
Dan Hess
·
08/22/2006 10:42 AM
·
Stocks
Etana Yes Hank McKinnell was replaced. My take is he was fired, that I see as good news however he still remains as chairman. I have seen some...
Pfizer (PFE)
· by
Hugh McManus
·
12/15/2006 08:37 PM
·
Stocks
Whoops! It looks like I posted my recent missive on Pfizer in the wrong thread! Sorry.
Pfizer (PFE)
· by
Dan Hess
·
12/15/2006 11:05 PM
·
Stocks
Hugh I am glad to hear you are still holding Pfizer although desiring a lower price to add to your holdings. I also continue to hold PFE. It does...
Pfizer (PFE)
· by
Sunil Veluvali
·
12/27/2006 06:11 PM
·
Stocks
Mr McKinnell presided ~ $140B drop in market cap from 1999-today. Replacing him is fine, but consider the competecy of the BOD that gave him $77m...
Pfizer (PFE)
· by
Mark Robertson
·
10/20/2009 01:56 PM
·
Stocks
Pfizer (PFE) today reported financial results for third-quarter 2009. Revenues were $11.6 billion, a decrease of 3% compared with $12.0 billion in...
Pfizer (PFE)
· by
Mark R. Johnson
·
10/24/2009 04:12 PM
·
Stocks
Pfizer (PFE) would make outstanding fodder for a case study. The background being sky-high estimates of growth and profitability several years ago,...
Pfizer (PFE)
· by
Mark R. Johnson
·
11/24/2009 08:03 PM
·
Stocks
Let’s see if I can cut-and-paste these historical Value Line records… I think the lesson to learn is in the forecast reductions from way back. Any...
Pfizer (PFE)
· by
Mark Robertson
·
11/24/2009 09:09 PM
·
Stocks
One comment that I’d have is that we regard Pfizer (PFE) as among the most misleading of all the chronicles we’ve looked at. :) Mark Robertson
Pfizer (PFE)
· by
Mark Robertson
·
12/19/2009 10:17 AM
·
Stocks
Where to start with this one? Pfizer (PFE) is one of the worst offenders and disappointments for those who invested during the front half of this...
Pfizer (PFE)
· by
Mark Robertson
·
12/19/2009 10:47 AM
·
Stocks
Sales Growth Forecast You can essentially ignore the (sales) historical data on a Stock Selection Guide. The large transactions render the...
Pfizer (PFE)
· by
Mark Robertson
·
12/19/2009 11:03 AM
·
Stocks
Preferred Procedure Summary Probably the best way to characterize expectations for Pfizer (until more details form post-merger) is to walk through...
Pfizer (PFE)
· by
Mark Robertson
·
12/19/2009 11:12 AM
·
Stocks
Summary and Conclusions When we’ve been bruised and battered, it can be difficult to set aside emotions. Value Line has a uniquely bleak outlook...
Pfizer (PFE)
· by
Dan Hess
·
12/19/2009 01:54 PM
·
Stocks
> What do you think? I agree PFE has been a disappointment the last decade and it is quite hard to analyze. I view the strength has been their...
Pfizer (PFE)
· by
Mark Robertson
·
12/20/2009 10:05 AM
·
Stocks
Lurker correspondence: Where do you get a 2% return forecast for Pfizer at Value Line? Thanks for the question. One of the things we’ve noticed is...
Pfizer (PFE)
· by
Dan Hess
·
01/20/2010 12:28 PM
·
Stocks
The voting for PFE shows little interest in this once Pharma giant. However I wonder if investors may be overlooking the transformation going on at...
Pfizer (PFE)
· by
Shelly Stokes
·
01/21/2010 09:32 PM
·
Stocks
I’m holding my Pfizer shares (and wishing I had purchased more during the meltdown.) I bought the shares for the dividend before it got cut, (of...
Pfizer (PFE)
· by
Dan Hess
·
02/01/2010 08:30 AM
·
Stocks
A Reuters article titled Pfizer expects to be No.1 in Japan generic drugs quoted from a PFE Japanese offical seems to support the new direction for...
Pfizer (PFE)
· by
Mark Robertson
·
03/07/2008 11:12 AM
·
Stocks
CNBC’s Mike Huckman reported on "Pfizer’s “Analyst Day”":http://seekingalpha.com/article/67475-analysts-react-to-pfizer-analyst-day and the early...
Pfizer (PFE)
· by
Mark Robertson
·
07/01/2020 01:16 PM
·
Stocks
Vaccine from Pfizer and BioNTech on the right track, early data show (Axios via Susan Maciolek)
Pfizer (PFE)
· by
Dan Hess
·
03/14/2011 12:19 PM
·
Stocks
Pfizer has had a rough period of stock performance. PFE has long been an active acquirer buying companies to make up for a weak drug pipeline....
Pfizer (PFE)
· by
Dan Hess
·
07/28/2011 09:53 AM
·
Stocks
Many Pfizer followers were surprised by the lack of details involving the firing of CEO Jeff Kindler last year. Fortune in their August 15 issue...
Pfizer (PFE)
· by
Mark Robertson
·
04/03/2013 09:11 AM
·
Stocks
Some commentary on biosimilars and potential: http://seekingalpha.com/article/1316881-biosimilars-could-be-an-unlikely-boost-for-pfizer
Pfizer (PFE)
· by
Dan Hess
·
04/03/2013 09:49 AM
·
Stocks
The biosimilars would seem to be a good fit with Pfizer’s extensive marketing force. i.e. They have to be sold against competitors. I admit to...
Pfizer (PFE)
· by
Dan Hess
·
04/03/2013 12:19 PM
·
Stocks
Mark The PFE longer term chart caught my attention. Using VL and the charts from my broker I found the all time high price was $49.25 in 2000....
Pfizer (PFE)
· by
Jeff Traeger
·
04/04/2013 02:31 AM
·
Stocks
Dan, “Thus it seems StockCharts adjusts for dividends as well as stock splits.” This is a new concept for me. Could you expand your thought? Does...
Pfizer (PFE)
· by
Dan Hess
·
04/04/2013 11:04 AM
·
Stocks
Yes you have it right. A clearer example may be a 2 for 1 stock split. The result being the stock price will be approximately half its pre split...
Pfizer (PFE)
· by
Mark Robertson
·
06/29/2022 08:13 PM
·
Stocks
Value Line Close (7/1/2022) The stock holds an Above Average (2)rank for Timeliness. PFE shares have pulled back 14% in price since our last report...
Pfizer (PFE)
· by
Mark Robertson
·
09/28/2022 01:54 PM
·
Stocks
Value Line Close (9/30/2022) The stock holds an average Timeliness. PFE shares have pulled back some this year to broader macro uncertainty and...
Pfizer (PFE)
· by
Mark Robertson
·
09/23/2023 07:56 AM
·
Stocks
CDC panel backs Pfizer’s maternal RSV vaccine. A Centers for Disease Control and Prevention advisory committee yesterday recommended administering...
Pfizer (PFE)
· by
Mark Robertson
·
09/23/2023 08:37 AM
·
Stocks
Equity Analysis (PFE) Completed spinoff of Upjohn (11/20). The addition of Seagen would also provide a significant boost. Pfizer announced...
Pfizer (PFE)
· by
Mark Robertson
·
10/16/2023 11:18 AM
·
Stocks
Via Grit Capital
Pfizer (PFE)
· by
Matt Spielman
·
12/01/2023 11:02 AM
·
Stocks
Pfizer is down 5% today, and 40% for the year, on news that it is stopping the trials for its twice-daily weight loss pill.. The trial was halted...
Pfizer (PFE)
· by
Mark Robertson
·
12/02/2023 09:23 AM
·
Stocks
Perhaps this is a threat to low-growth Pfizer and a potential departure from the Manifest Investing 40? Making room for growth?
Pfizer (PFE)
· by
Sandra Caster
·
12/02/2023 09:53 AM
·
Stocks
https://invest.kleinnet.com/bmw1/stats40/PFE.html If you believe in reversion to the mean this may be the wrong time to sell PFE… it could bounce...
Pfizer (PFE)
· by
Mark Robertson
·
12/14/2023 08:02 AM
·
Stocks
The Dow hit an all-time high yesterday after the Fed hinted at plans to make multiple rate cuts next year. Not having such a good day was Pfizer,...
Pfizer (PFE)
· by
Mark Robertson
·
12/23/2023 10:29 AM
·
Stocks
Equity Analysis (PFE) Value Line Close (12/29/2023) The stock holds an Average (3) rank for Timeliness. PFE has shed 20% in value since our last...
Pfizer (PFE)
· by
Mark Robertson
·
02/11/2024 02:06 PM
·
Stocks
Jim, we use the Projected Dividend Yield (3.8%) for the projected annual return calculation. The 6.2% is the Current Yield.
Pfizer (PFE)
· by
Mark Robertson
·
03/24/2024 12:33 PM
·
Stocks
The Pfizer (PFE) stock price is at a 10-year low. Equity Analysis (PFE) Value Line Open & Close (3/29/2024) *Pfizer is looking to rebound from...
Pfizer (PFE)
· by
Mark Robertson
·
05/23/2024 11:07 AM
·
Stocks
Pfizer announced a new round of cost-cutting measures that are intended to garner $1.5 billion in savings by the end of 2027. The multi-year...
Pfizer (PFE)
· by
Mark Robertson
·
06/22/2024 01:31 PM
·
Stocks
Equity Analysis (PFE) Value Line Open (6/28/2024) Pfizer delivered better-than-expected first-quarter results. GAAP earnings and sales declined 43%...
Pfizer (PFE)
· by
Mark Robertson
·
09/23/2024 01:48 PM
·
Stocks
Equity Analysis (PFE) Value Line Close (9/27/2024) The stock holds an average rank for Timeliness. Our longer-term projections suggest attractive...
Pfizer (PFE)
· by
Nick A DiVirgilio
·
09/24/2024 03:15 PM
·
Stocks
The first (and only) line item that jumped out at me was the "Calculated EPS Growth Forecast of 60.7%. Compare this to the "Regression EPS Growth...
Pfizer (PFE)
· by
Mark Robertson
·
10/08/2024 10:44 AM
·
Stocks
Pfizer is reportedly being targeted by activist investor Starboard Value, which is said to have sought help from two faces that will be familiar to...
Shortcomings of Bread Crumbs
· by
Mark Robertson
·
08/14/2008 08:43 PM
·
General Discussion
The Pfizer 2002 financial summary is available here as an attachment.